Andrew Henry

1.1k total citations
15 papers, 638 citations indexed

About

Andrew Henry is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Andrew Henry has authored 15 papers receiving a total of 638 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 11 papers in Radiology, Nuclear Medicine and Imaging and 3 papers in Oncology. Recurrent topics in Andrew Henry's work include Monoclonal and Polyclonal Antibodies Research (10 papers), Glycosylation and Glycoproteins Research (6 papers) and Protein purification and stability (5 papers). Andrew Henry is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (10 papers), Glycosylation and Glycoproteins Research (6 papers) and Protein purification and stability (5 papers). Andrew Henry collaborates with scholars based in United Kingdom, United States and Germany. Andrew Henry's co-authors include Anthony R. Rees, David M. Webster, Stephen Searle, Michael Roguska, Braydon C. Guild, Jan T. Pedersen, John M. Lambert, W A Blättler, V S Goldmacher and Dirk Laurent and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Journal of Molecular Biology.

In The Last Decade

Andrew Henry

15 papers receiving 610 citations

Peers

Countries citing papers authored by Andrew Henry

Since Specialization

Citations

This map shows the geographic impact of Andrew Henry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Henry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Henry more than expected).

Fields of papers citing papers by Andrew Henry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Henry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Henry. The network helps show where Andrew Henry may publish in the future.

Co-authorship network of co-authors of Andrew Henry

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Henry. A scholar is included among the top collaborators of Andrew Henry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Henry. Andrew Henry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Predicting deamidation and isomerization sites in therapeutic antibodies using structure-based in silico approaches 2024 ·mAbs ·(unknown), (unknown), (unknown), Andrew Henry, Anne R. Karow‐Zwick, Giuseppe Licari	2
2	A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer 2007 ·Annals of Oncology ·Anne Thomas, Tanja Trarbach, (unknown), Dirk Laurent, Andrew Henry, (unknown), Jim J. Wang, Eric Masson, W P Steward, U. Vanhoefer, Bertram Wiedenmann	40
3	Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials 2005 ·Annals of Oncology ·Joachim Drevs, Ute Zirrgiebel, (unknown), K. Mross, Michael Medinger, (unknown), José Cirı́aco Pinheiro, J M Wood, Anne Thomas, Clemens Unger, Andrew Henry, William P. Steward, Dirk Laurent, David Lebwohl, Margaret Dugan, Dieter Marmé	95
4	Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies 2003 ·Journal of Clinical Oncology ·Bruno Morgan, Anne Thomas, Joachim Drevs, (unknown), Martin Büchert, (unknown), Mark A. Horsfield, (unknown), Howard Ball, (unknown), William Mietlowski, Stefan Fuxius, Clemens Unger, Kenneth J. O’Byrne, Andrew Henry, Graham R. Cherryman, Dirk Laurent, Margaret Dugan, Dieter Marmé, William P. Steward	16
5	561 Clinical results from an ADME (absorption, distribution, metabolism, and excretion) trial of PTK787/ZK 222584 (PTK/ZK): a novel, oral angiogenesis inhibitor in patients with advanced cancer 2003 ·European Journal of Cancer Supplements ·Juergen A. Knoblich, Päivi M. Paldánius, Hans-Peter Gschwind, (unknown), Andrew Henry, Jiaxuan Xia, Dirk J. Reitsma, Dirk Laurent, L.M. Jost	1
6	Reduced antibody response to streptavidin through site‐directed mutagenesis 2001 ·Protein Science ·Damon L. Meyer, Jody Schultz, Yukang Lin, Andrew Henry, James Sanderson, Jeffrey M. Jackson, (unknown), Anthony R. Rees, Scott S. Graves	63
7	Phase I dose escalation, pharmacokinetic (pk) study of a novel vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK) 1999 ·European Journal of Cancer ·Joachim Drevs, (unknown), Petra Reusch, Boya Peng, Howard Ball, Andrew Henry, Dirk Laurent, Margaret Dugan, Dieter Marmé, Clemens Unger	4
8	Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody. 1999 ·PubMed ·Scott S. Graves, (unknown), Diane Stone, Don B. Axworthy, John M. Reno, (unknown), Stephen M. J. Searle, Andrew Henry, Jan T. Pedersen, Anthony R. Rees, Randell T. Libby	8
9	A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing 1996 ·Protein Engineering Design and Selection ·Michael Roguska, Jan T. Pedersen, Andrew Henry, Stephen M. J. Searle, (unknown), Brian J. Avery, (unknown), (unknown), John M. Lambert, Walter A. Blättler, Anthony R. Rees, Braydon C. Guild	40
10	Antibody design: Beyond the natural limits 1994 ·Trends in biotechnology ·Anthony R. Rees, David Staunton, David M. Webster, Stephen Searle, Andrew Henry, Jan T. Pedersen	30
11	Humanization of murine monoclonal antibodies through variable domain resurfacing. 1994 ·Proceedings of the National Academy of Sciences ·Michael Roguska, (unknown), (unknown), Andrew Henry, Stephen Searle, John M. Lambert, V S Goldmacher, W A Blättler, Anthony R. Rees, Braydon C. Guild	159
12	Comparison of Surface Accessible Residues in Human and Murine Immunoglobulin Fv Domains 1994 ·Journal of Molecular Biology ·Jan T. Pedersen, Andrew Henry, Stephen Searle, Braydon C. Guild, Michael Roguska, Anthony R. Rees	43
13	Antibody-antigen interactions 1994 ·Current Opinion in Structural Biology ·David M. Webster, Andrew Henry, Anthony R. Rees	7
14	Antibody-antigen interactions 1994 ·Current Opinion in Structural Biology ·David M. Webster, Andrew Henry, Anthony R. Rees	111
15	Antibody modeling: Beyond homology 1992 ·Jan T. Pedersen, Stephen M. J. Searle, Andrew Henry, Anthony R. Rees	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact